查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023年至2028年控制释放给药市场预测
市场调查报告书
商品编码
1410091

2023年至2028年控制释放给药市场预测

Controlled Release Drug Delivery Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球控制释放给药市场预计在预测期内复合年增长率为 6.93%。

允许活性药物成分 (API) 长时间受控释放的控释药物给药称为药物递送。与控制释放药物输送相关的众多好处和慢性病负担的增加是控制释放药物输送市场的主要成长动力。此外，人口老化需要受控药物、有利的政府法规以及各种科学研究的技术开拓也有望加强控制释放药物输送市场。

控制释放药物传递的多重好处

使用控制释放药物递送系统，可以将治疗药物浓度长时间维持在适当的范围内。控制释放可透过维持体内恆定的药物浓度来改善药物治疗。控制释放给药系统透过减少剂量次数来提高病患的依从性。减少用药频率通常对患者来说更方便，并且可以改善结果。因此，对以持续方式释放药物并消除频繁给药的需要的控制释放製剂的需求日益增长，这有望推动控制释放药物递送市场。

慢性病盛行率增加

控制释放药物传递提供更好的治疗效果、更少的剂量变异性和更高的疗效，特别是在慢性疾病。因此，慢性病患者数量的增加有望推动控制释放给药市场的发展。世界卫生组织（WHO）估计，2019年全球死亡人数中有71%是由慢性病造成的。这包括糖尿病、癌症、慢性呼吸道疾病和心血管疾病等疾病。心血管疾病（CVD）是一种影响世界大部分地区的主要慢性疾病。根据世界卫生组织估计，2019年全球有1,790万人死亡，占总死亡人数的32%。

不断成长的学名药市场

控制释放非专利製剂具有与品牌药物相当的缓释特性。为了扩大市场，学名药製造商正在投资开发知名药物的控制释放製剂。学名药的成本效益和不断上涨的医疗费用正在推动对学名药的需求。世界各国政府已引入法律规范以促进学名药的生产和使用。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）制定了学名药许可法规，以确保仿製药遵守与学名药药相同严格的品质、安全性和功效标准。我已经创建了一条路径。

研发费用增加

各种科学研究以及该领域有利的资助计划正在推动控制释放药物输送市场的发展。 NIBIB 支持生物医学影像和生物工程（包括药物传输系统）的研究和开发。 NIBIB 资助旨在开发新型药物输送系统、提高治疗效果和安全性以及提高患者依从性的措施。此外，全球医疗保健支出的增加正在推动控制释放给药市场的成长。例如，世界卫生组织预测，2020年全球卫生支出总额将占全球GDP的近10%。此外，根据美国研究组织的数据，与 2019 年相比，2020 年美国医疗保健研发支出增加了约 11%。

人口老化

市场扩张的关键驱动力之一是全球老年人和儿童人口的增加，部分原因是这些年龄层中不遵守处方药物时间表的比例很高。例如，根据联合国报告《2019年世界人口展望》，到2050年，60岁及以上的人口预计将增加一倍以上，达到21亿人，占世界人口的20%以上。在人口老化中，老年人的身体、心理和生物能力正在下降，这影响了药物的吸收。此外，他们的身体无法忍受令人不快的副作用和过量的剂量。因此，由于患者人数迅速增加和人口老化，控制释放给药市场预计将扩大。

北美地区预计将大幅成长

预计在预测期内，北美地区将占据控制释放给药市场的主要份额。造成这一比例的因素包括慢性病盛行率高、医疗保健支出增加、政府法规、老年人口不断增长以及技术进步。例如，根据美国疾病管制与预防中心 (CDC) 的数据，到 2020 年，大约十分之六的美国成年人将患有至少一种慢性病，十分之四的人将患有两种或两种以上慢性病。我坚持。此外，美国学名药产业的扩张也是控制释放给药市场的一个主要因素。

主要市场参与者

Adair Pharma Solutions 是一家跨国合约开发和受託製造厂商(CDMO)，专门从事口服剂型（包括控制释放製剂）的开发和製造。该公司的技术包括多颗粒配方、基质系统、渗透系统和包衣颗粒。这些技术允许控制和增强持续药物释放引起的药物释放曲线。卡乐康是为製药和营养补充食品提供尖端解决方案和技术支援的全球领导者。该公司的 Opadry® 薄膜包衣用于改善口服固体製剂（包括控制释放製剂）的耐久性和外观。一家总部位于美国的全球製药公司。是一家总部位于美国的全球製药公司，生产和销售各种医药产品，包括品牌处方药和非处方药。该公司的产品包括Keytruda®（派姆单抗）、Januvia®（sitagliptin）、 Gardasil （人类乳突病毒疫苗）和Proquad®（麻疹和水痘疫苗）。

市场主要发展

2022年3月，FDA核准Corium的ADLARITY（经皮）用于治疗轻度、中度和重度老年痴呆症失智症。 2020 年 1 月，医疗技术公司美敦力 (Medtronic) 开发了用于脊髓刺激的 Intelis 平台。为了治疗慢性疼痛，该平台利用控制释放药物传递。它将电刺激设备与植入式药物帮浦结合起来，随着​​时间的推移提供有针对性的疼痛治疗。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章控制释放给药市场：依技术分类

  • 介绍
  • 微胶囊化
  • 经皮的
  • 定向投放
  • 其他的

第六章控制释放给药市场：依释放机制

  • 介绍
  • 基于聚合物的系统
  • 微储库分区控制给药系统
  • 回馈调节给药系统
  • 活化调节的药物输送系统
  • 化学活化

第七章控制释放给药市场：依应用

  • 介绍
  • 定量吸入器
  • 可注射的
  • 经皮吸收贴片和眼科贴剂
  • 其他的

第八章控制释放给药市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Adare Pharma Solutions
  • Merck and Co., Inc
  • Colorcon
  • Coating Place
  • GlaxoSmithKline PLC
  • Lonza
  • Bayer Healthcare LLC
  • Orbis Biosciences Inc.
  • Alkermes PLC
  • Pfizer Inc.
简介目录
Product Code: KSI061615754

The global controlled release drug delivery market is estimated to grow at a CAGR of 6.93% during the forecast period.

Managed release drug administration that allows for a prolonged, controlled release of the active pharmaceutical ingredient (API) is referred to as controlled drug delivery. Numerous benefits associated with controlled drug delivery and the growing burden of chronic diseases are major growth drivers in the controlled-release drug delivery market. Moreover, the ageing population with the requirement for controlled drugs, favourable government regulations, and technological developments owing to various scientific research are also expected to bolster the controlled release drug delivery market.

Multiple Associated Benefits of Controlled Release Drug Delivery

Drug levels intended for therapeutic use are kept within the proper range for a longer length of time using controlled-release drug delivery systems. By guaranteeing a constant drug concentration in the body, this controlled release of medication might enhance drug therapy. Reduced dose frequency provided by controlled-release medication delivery systems enhances patient compliance. Less frequent drug use is typically more convenient for patients, which can improve treatment outcomes. The need for controlled-release formulations that offer continuous medication release and eliminate the requirement for frequent dosing is thus on the rise and thereby contemplated to propel the controlled-release drug delivery market.

Increasing Prevalence of Chronic Disease

Controlled-release drug delivery can lead to better treatment results, fewer medication level variations, and greater efficacy, especially in chronic diseases. Thus, the rising cases of chronic illness are contemplated to boost the controlled-release drug delivery market. The World Health Organisation (WHO) estimates that 71% of deaths worldwide in 2019 were caused by chronic diseases. This covers conditions like diabetes, cancer, chronic respiratory conditions, and cardiovascular illnesses. Cardiovascular disease (CVD) is a major chronic disease contributing significant portions worldwide. The WHO estimates that 17.9 million deaths worldwide in 2019 were caused by CVDs, accounting for 32% of all fatalities.

Growing Generic Drug Market

Generic formulations with controlled release provide prolonged release properties comparable to those of their branded equivalents. To expand the market, generic drug producers are making investments in the creation of controlled-release versions of well-known medications. The cost-effectiveness of generic medications and rising healthcare costs are driving up demand for them. Governments all over the world implemented regulatory frameworks to encourage the creation and utilization of generic medications. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) developed paths for the licensing of generic medications, ensuring that they adhere to the same exacting quality, safety, and efficacy criteria as name-brand medications.

Rising Research and Development Expenditure

Various scientific research studies along with the favourable funding programs in the concerned field are propelling the controlled-release drug delivery market. Research and development in biomedical imaging and bioengineering which covers topics including drug delivery systems, is supported by NIBIB. They provide funding for initiatives aimed at creating novel drug delivery systems, promoting therapeutic efficacy and safety, and raising patient compliance. Additionally, the global rising healthcare expenditure is augmenting the controlled-release drug delivery market growth. For instance, WHO predicted that in 2020, total global healthcare spending accounted for almost 10% of the world's GDP. Moreover, the healthcare R&D expenditure in the USA increased by around 11% in 2020 as compared to 2019 according to the Research America Organization.

Aging Population

One of the key drivers of market expansion is the growing worldwide geriatric and pediatric population, which is partly attributable to these age groups' high rates of non-adherence to prescribed medication schedules. For instance, according to the World Population Prospects 2019 report from the United Nations, the number of persons 60 and older is predicted to more than double by 2050, reaching 2.1 billion, or more than 20% of the world's population. Intake of medications is impacted in geriatric populations due to impaired physical, mental, and biological capabilities. Additionally, their body is unable to withstand the unpleasant side effects and excessive doses of medication. Therefore, the controlled-release drug delivery market is contemplated to bolster due to a sharp increase in the patient population and aging population.

North America is Expected to Grow Significantly

The North American region is projected to hold a significant share of the controlled release drug delivery market during the forecasted period. Various factors attributed to such a share are the higher prevalence of chronic disease, increasing healthcare expenditures, government regulation, growing geriatric population, and technological advancements. For instance, approximately 6 in 10 adult Americans were suffering from at least one chronic disease by 2020, and 4 in 10 were having two or more chronic disorders, according to the Centres for Disease Control and Prevention (CDC). Additionally, the widening generic medicine industry in the USA is another major factor in the controlled-release drug delivery market.

Major Market Players

  • Adare Pharma Solutions is a multinational contract development and manufacturing organization (CDMO) that specializes in the creation and production of oral dosage forms, including formulations with controlled release. Multiparticulates, matrix systems, osmotic systems, and coated pellets are technologies used by to company. These technologies allow for the controlled and extended drug release profiles that result from sustained drug release.
  • Colorcon is a world leader in terms of providing cutting-edge solutions and technical support to the pharmaceutical and dietary supplement sectors. The company's Opadry® film coatings are used to improve the durability and appearance of oral solid dosage forms, including controlled-release formulations.
  • Merck & Co., Inc. is a global pharmaceutical corporation with its corporate headquarters in the United States. Merck manufactures and distributes a wide selection of pharmaceutical goods, including both branded prescription drugs and over-the-counter (OTC) items. Products offered by the company are Keytruda® (pembrolizumab), Januvia® (sitagliptin), Gardasil® (human papillomavirus vaccination), and ProQuad® (measles, and varicella vaccine).

Key Market Developments

  • In March 2022, the FDA approved Corium's ADLARITY (donepezil transdermal system) as a treatment for those with mild, moderate, or severe Alzheimer's-related dementia, according to Corium, Inc.
  • In January 2020, the Intellis platform for spinal cord stimulation was developed by the medical technology company Medtronic. To treat chronic pain, this platform makes use of controlled-release drug delivery. It combines an electrical stimulation device with an implanted medication pump to deliver targeted pain treatment over time.

Segmentation:

By Technology

  • Micro Encapsulation
  • Transdermal
  • Targeted delivery
  • Others

By Release Mechanism

  • Polymer Based Systems
  • Micro Reservoir Partition Controlled Drug Delivery Systems
  • Feedback Regulated Drug Delivery Systems
  • Activation-modulated Drug Delivery Systems
  • Chemically Activated

By Application

  • Metered Dose Inhalers
  • Injectable
  • Transdermal and Ocular Patches
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. CONTROLLED RELEASE DRUG DELIVERY MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Micro Encapsulation
  • 5.3. Transdermal
  • 5.4. Targeted delivery
  • 5.5. Others

6. CONTROLLED RELEASE DRUG DELIVERY MARKET, BY RELEASE MECHANISM

  • 6.1. Introduction
  • 6.2. Polymer Based Systems
  • 6.3. Micro Reservoir Partition Controlled Drug Delivery Systems
  • 6.4. Feedback Regulated Drug Delivery Systems
  • 6.5. Activation-modulated Drug Delivery Systems
  • 6.6. Chemically Activated

7. CONTROLLED RELEASE DRUG DELIVERY MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Metered Dose Inhalers
  • 7.3. Injectable
  • 7.4. Transdermal and Ocular Patches
  • 7.5. Others

8. CONTROLLED RELEASE DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Adare Pharma Solutions
  • 10.2. Merck and Co., Inc
  • 10.3. Colorcon
  • 10.4. Coating Place
  • 10.5. GlaxoSmithKline PLC
  • 10.6. Lonza
  • 10.7. Bayer Healthcare LLC
  • 10.8. Orbis Biosciences Inc.
  • 10.9. Alkermes PLC
  • 10.10. Pfizer Inc.